31. An isolated polynucleotide encoding the ABM or antibody of any of claims 1-30.

32. A vector comprising the polynucleotide of claim 31.

33. A host cell comprising the vector of claim 32.

34. A composition comprising the ABM or antibody of any of claims 1-30 and a pharmaceutically acceptable carrier.

35. A method of inducing cell lysis of a tumor cell, the method comprising contacting the tumor cell with the ABM or antibody of any of claims 1-30 or the composition of claim 34.

36. The method of claim 35, wherein the tumor cell is selected from the group consisting of a colorectal cancer cell, NSCLC (non-small cell lung cancer), gastric cancer cell, pancreatic cancer cell and breast cancer cell.

37. The method of claim 35, wherein the cell lysis is induced by antibody dependent cell cytotoxicity of the ABM or antibody.

38. A method of treating a subject having a cancer that abnormally expresses CEA, the method comprising administering to the subject a therapeutically effective amount of the ABM or antibody of any one of claims 1-30 or the composition of claim 34.

39. A method of increasing survival time in a subject having a cancer that abnormally expresses CEA, the method comprising administering to the subject a therapeutically effective amount of the ABM or antibody of any one of claims 1-30 or the composition of claim 34.

40. The method of claim 38 or 39, wherein the cancer is selected from the group consisting of colorectal cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer and breast cancer.

41. The method of any of claims 35-40, wherein the ABM or antibody or composition is administered in combination with chemotherapy or radiation therapy.

42. The method of any of claims 35-41, wherein the subject is a human.

43. Use of the ABM or antibody of any of claims 1-30 or the composition of claim 34 in the manufacture of a medicament for treating a subject having a cancer that abnormally expresses CEA.

44. The use of claim 43, wherein the cancer is selected from the group consisting of colorectal cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer and breast cancer.

~~45. The invention as described hereinabove.~~